In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Creative BioMolecules Inc.

Division of Curis Inc.

Latest From Creative BioMolecules Inc.

Kyphon: A Trial Balloon Succeeds in Spine

Until now, most spine surgeons wouldn't even treat osteoporotic fractures of the spine, referring such patients to medical management. But using technology borrowed from balloon angioplasty, Kyphon has developed instrumentation that represents a new clinical approach to this serious problem. As with most device companies, regulatory issues and reimbursement have been a challenge, as have comparisons with another spinal procedure, vertebroplasty.
Medical Device Regulation

Tanox: Once Is Not Enough

Double-digit royalties from the sales of an expected blockbuster allergy and asthma drug make Tanox a biotech player. But it still hasn't proven itself as a drug developer. Where does Tanox go from here?The company has a significant share of E25, a monoclonal antibody now under worldwide regulatory review as an asthma/allergy treatment. Tanox partnered its anti-IgE progam with Novartis (then Ciba-Geigy) in 1990. After Genentech disclosed its own anti-IgE program in 1993, triggering a lawsuit by Tanox and Novartis, the parties settled and Genentech also became a partner. The tripartite collaboration picked E25--Genentech's compound--for development a year later. Since then, Tanox's collaborators have shouldered the responsibility for commercialization of E25. It effectively lost the chance to build a commercial infrastructure around a major program and demonstrate its ability to manage late-stage product development. However, having large-company partners did enable Tanox to begin building a modest pipeline with early-stage in-licensed and homegrown products, including Hu 901, its own anti-IgE antibody now in human testing for severe peanut allergies. Tanox also significantly enhanced its power to partner when it went public in April, raising $226 million. It now sports a roughly $2 billion valuation. To drive growth and be more than a revenue stream for E25, however, management must now demonstrate a new range of deal-making and development capabilities.
BioPharmaceutical

Ontogeny Grows the Family Tree

The merger of Creative BioMolecules, Ontogeny, and Reprogenesis to form Curis Inc. was designed to build value long-term. Driven by their common focus on regenerative medicine, Curis combines near-term and longer-term product opportunities and creates a more formidable discovery engine to compete with larger companies in the field.
BioPharmaceutical Business Strategies

THM Biomedical Inc.

THM Biomedical Inc. has been quietly fabricating bioresorbable architectures useful in tissue engineering for years. The company begins with a well-known biocompatible material, an amorphous form of polylactic acid, and it creates open-celled three-dimensional architectures that suit a wide range of applications in tissue repair and reconstruction.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Headquarters
  • Parent & Subsidiaries
  • Curis Inc.
  • Senior Management
  • Contact Info
  • Creative BioMolecules Inc.
    ,
Advertisement
Advertisement
UsernamePublicRestriction

Register